GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Enterprise Value

Sinovac Biotech (Sinovac Biotech) Enterprise Value : $-6,773.0 Mil (As of May. 01, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sinovac Biotech's Enterprise Value is $-6,773.0 Mil. Sinovac Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-963.9 Mil. Therefore, Sinovac Biotech's EV-to-EBIT ratio for today is 7.03.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Sinovac Biotech's Enterprise Value is $-6,773.0 Mil. Sinovac Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-800.9 Mil. Therefore, Sinovac Biotech's EV-to-EBITDA ratio for today is 8.46.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Sinovac Biotech's Enterprise Value is $-6,773.0 Mil. Sinovac Biotech's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $420.9 Mil. Therefore, Sinovac Biotech's EV-to-Revenue ratio for today is -16.09.


Sinovac Biotech Enterprise Value Historical Data

The historical data trend for Sinovac Biotech's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Enterprise Value Chart

Sinovac Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 369.04 515.37 -23.77 -8,078.03 -6,802.99

Sinovac Biotech Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,743.27 -8,078.03 -6,494.78 -6,802.99 -6,589.44

Competitive Comparison of Sinovac Biotech's Enterprise Value

For the Biotechnology subindustry, Sinovac Biotech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinovac Biotech's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's Enterprise Value falls into.



Sinovac Biotech Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Sinovac Biotech's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

Sinovac Biotech's Enterprise Value for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinovac Biotech  (NAS:SVA) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Sinovac Biotech's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-6772.969/-963.875
=7.03

Sinovac Biotech's current Enterprise Value is $-6,773.0 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sinovac Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-963.9 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Sinovac Biotech's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=-6772.969/-800.888
=8.46

Sinovac Biotech's current Enterprise Value is $-6,773.0 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sinovac Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-800.9 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Sinovac Biotech's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-6772.969/420.875
=-16.09

Sinovac Biotech's current Enterprise Value is $-6,773.0 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sinovac Biotech's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $420.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinovac Biotech Enterprise Value Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinovac Biotech (Sinovac Biotech) Business Description

Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Executives
Lily Wang director, 10 percent owner, officer: Chief Financial Officer 300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc 10 percent owner PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong director, 10 percent owner, officer: President and CEO
Terry G Bowering director, 10 percent owner, officer: President, CEO 10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6

Sinovac Biotech (Sinovac Biotech) Headlines

From GuruFocus

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

By Business Wire Business Wire 06-25-2022